Santiago - Delayed Quote USD

Merck & Co., Inc. (MRK.SN)

78.71

+2.05

+(2.67%)

At close: April 25 at 10:09:20 AM GMT-4

Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference

RAHWAY, N.J., May 22, 2025--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Business Wire yesterday

MRK
Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation

In a recent development, Antengene Corporation Limited announced a global clinical collaboration with Merck (NYSE:MRK) to evaluate ATG-022 in combination with KEYTRUDA®, which could enhance Merck's oncology portfolio. Despite this collaboration and other positive product-related announcements, Merck’s stock price was relatively flat over the past month at a 1% decline. During this time, the broader market posted gains, driven by easing trade concerns and strong corporate earnings. The...

Simply Wall St. 2 days ago

MRK
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

BASKING RIDGE, N.J. & RAHWAY, N.J., May 19, 2025--The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus investigator’s choice of chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with disease progression following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.

Business Wire 4 days ago

MRK

DSKYF

DSNKY
The Top Corporate Board Directors

Who are the most influential directors at big publicly traded U.S. companies? The first annual Wall Street Journal ranking identifies 251 of them.

The Wall Street Journal 4 days ago

LMT

CVX

CAT
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension

RAHWAY, N.J., May 16, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society’s (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck’s commitment to advancing research for patients with this disease.

Business Wire 7 days ago

MRK
FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma

The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, or PPGL. “This represents the first FDA approval of an oral therapy for PPGL,” the FDA stated. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on M

TipRanks 7 days ago

MRK
Jefferies not seeing significant impact to Merck, Bristol from draft guidance

Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single source qualifying drugs. The updated language on single source qualifying fixed dose combo products in the draft makes it seem as if subcutaneous Keytruda/Opdivo will be eligible for negotiation in 2028, but “We’re not sure this is true,” says the analyst, who is not seeing a significant impact to Merck

TipRanks 7 days ago

BMY

CELG-RT

MRK
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

RAHWAY, N.J., May 15, 2025--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer

Business Wire 8 days ago

MRK
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

RAHWAY, N.J., May 14, 2025--WELIREG PPGL FDA Approval News Release

Business Wire 8 days ago

MRK
Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint. However, the company experienced a 3% decline in its share price last week, during a period when broader market indices, led by tech gains, posted positive returns. Despite this decline, Merck's ongoing initiatives in cancer treatment and digital health technologies signal sustained efforts against...

Simply Wall St. 8 days ago

MRK
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025

RAHWAY, N.J., May 13, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple treatment settings from the company’s broad and differentiated portfolio and pipeline will be showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30–June 3). Data highlight Merck’s commitment to rapidly advance research across multiple tumor types and continue to build on its portfolio of e

Business Wire 10 days ago

MRK
Trump's drug price order is part request, part threat: Analyst

President Trump signed an executive order on Monday calling for pharmaceutical companies to cut their drug prices for US consumers. Bernstein Senior Analyst, US Biopharmaceuticals Courtney Breen comments on whether the Trump administration ultimately has the power to force drug companies to do this. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 10 days ago

LLY

ABBV

AMGN
How Trump could go about executing order to slash drug prices

President Trump signed an executive order on Monday asking drugmakers to cut prices on their prescription drugs. Yahoo Finance consumer affairs reporter Jordan Weissmann reviews Trump's latest push to slash drug costs and how the administration may seek to go about it. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 10 days ago

MRK

AMGN

ABBV
Drug wars: Wall Street says big questions remain about impact of Trump's new pricing order

Trump signed a new executive order Monday that would attempt to force drugmakers to lower pricing in the US compared to other developed nations.

Yahoo Finance 10 days ago

BMY

CELG-RT

PFE
Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers

The "Magnificent Seven," made up of Nvidia (NVDA), Alphabet (GOOG, GOOGL), Tesla (TSLA), Microsoft (MSFT), Amazon (AMZN), Meta (META), and Apple (AAPL), are rallying after the US and China agreed to lower tariff rates for a 90-day period. Airline stocks, like American Airlines (AAL), Delta (DAL), and United Airlines (UAL), are also gaining on the trade deal. Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck (MRK), are moving to the downside after US President Trump said he will cut drug prices by over 50%. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 10 days ago

GOOG

MSFT

UAL
Shareholders Will Be Pleased With The Quality of Merck's (NYSE:MRK) Earnings

The subdued stock price reaction suggests that Merck & Co., Inc.'s ( NYSE:MRK ) strong earnings didn't offer any...

Simply Wall St. 14 days ago

MRK
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

RAHWAY, N.J., May 08, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health’s manufacturing facility in De Soto, Kansas.

Business Wire 15 days ago

MRK
Is Merck & Co., Inc. (MRK) the Best Dow Stock?

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength […]

Insider Monkey 15 days ago

MRK
Merck (NYSE:MRK) Launches Next-Gen Digital Ecosystem for Growth Disorders with Dawn Health

Merck (NYSE:MRK) recently announced the launch of a next-generation digital ecosystem for Growth Hormone Deficiency, a move that underscores its commitment to innovative patient care. This development adds a counterbalance to broader market trends, where mixed investor sentiment is influenced by anticipation of Federal Reserve interest rate decisions and ongoing trade discussions. While Merck's shares declined by 3% over the last month, this shift aligns with the flat market performance,...

Simply Wall St. 15 days ago

MRK
Merck & Co., Inc. (MRK): A Bull Case Theory

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Investing Intel. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s share was trading at $84.71 as of April 29th. MRK’s trailing and forward P/E were 12.31 and 9.45 respectively according to Yahoo Finance. Merck’s […]

Insider Monkey 15 days ago

MRK

Performance Overview

Return	MRK.SN	S&P 500 (^GSPC)
YTD	-38.50%	-0.67%
1-Year	-35.63%	+10.08%
3-Year	-2.57%	+49.74%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck & Co., Inc. (MRK.SN)

Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

The Top Corporate Board Directors

Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension

FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma

Jefferies not seeing significant impact to Merck, Bristol from draft guidance

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting

Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025

Trump's drug price order is part request, part threat: Analyst

How Trump could go about executing order to slash drug prices

Drug wars: Wall Street says big questions remain about impact of Trump's new pricing order

Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers

Shareholders Will Be Pleased With The Quality of Merck's (NYSE:MRK) Earnings

Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

Is Merck & Co., Inc. (MRK) the Best Dow Stock?

Merck (NYSE:MRK) Launches Next-Gen Digital Ecosystem for Growth Disorders with Dawn Health

Merck & Co., Inc. (MRK): A Bull Case Theory

Performance Overview